Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 10INDUSTRY 3NIH 2NETWORK 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1NET 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Neoplasms 805Carcinoma, Non-Small-Cell Lung 768Breast Neoplasms 731Neoplasm Metastasis 341Colorectal Neoplasms 340Prostatic Neoplasms 324Multiple Myeloma 309Melanoma 305Recurrence 237Ovarian Neoplasms 237Leukemia, Myeloid, Acute 236Lymphoma, Non-Hodgkin 213Lung Neoplasms 211Carcinoma, Renal Cell 200Lymphoma 190Lymphoma, Follicular 164Pancreatic Neoplasms 157Leukemia, Lymphocytic, Chronic, B-Cell 149Carcinoma, Hepatocellular 140Stomach Neoplasms 137Leukemia 133Head and Neck Neoplasms 128Lymphoma, Large B-Cell, Diffuse 126Parkinson Disease 4, Autosomal Dominant Lewy Body 120Squamous Cell Carcinoma of Head and Neck 110Urinary Bladder Neoplasms 109Carcinoma 101Small Cell Lung Carcinoma 99Triple Negative Breast Neoplasms 97Glioblastoma 96

Interventions

Sunitinib 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Adenoma, Islet Cell × Clear all
NCT02264665 2023-11-13

OPALINE

Pfizer

Completed
144 enrolled 26 charts

Adenoma, Islet Cell

NCT00428220 2019-06-27

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Pfizer

Phase NA Completed
223 enrolled 8 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Somatostatinoma, Thyroid Neoplasms, Gastrointestinal Stromal Tumors

NCT01374451 2016-12-20

COOPERATE-2

Novartis

Phase 2 Terminated
160 enrolled 17 charts
EndocrineNET

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡